High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial
- 11 March 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Haematology
- Vol. 6 (4), e217-e228
- https://doi.org/10.1016/s2352-3026(19)30014-6
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myelomaLeukemia, 2012
- Improper analysis of trials randomised using stratified blocks or minimisationStatistics in Medicine, 2011
- The pathogenesis and diagnosis of acute kidney injury in multiple myelomaNature Reviews Nephrology, 2011
- Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma KidneyJournal of the American Society of Nephrology, 2011
- Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II StudyJournal of Clinical Oncology, 2010
- Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off HemodialysisClinical Journal of the American Society of Nephrology, 2009
- European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trialTrials, 2008
- Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple MyelomaJournal of the American Society of Nephrology, 2007
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958